Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Recent CMO promotion/ announcement

<< Previous

Bullboard Posts

Next >>

Comment by Kswdeluxon Dec 27, 2021 5:03pm

176 Views

Post# 34264412

RE:RE:RE:RE:RE:RE:RE:RE:Recent CMO promotion/ announcement

Yes, and it was the same for AWARE-1 with Roche, and it still sounds like we have not seen the final final AWARE-1 yet. Roche's agreement said ONC could not relrease final results until approved by Roche. So not sure what is up there still.

<< Previous

Bullboard Posts

Next >>

A Look into the Future of Chronic Pain Management